COVID-19 Pandemic – Consilient Health Statement

Consilient Health wish to acknowledge and thank our health care professionals for the vital care they have provided to Irish patients throughout the COVID-19 pandemic.

In response to the COVID-19 pandemic, Consilient Health has put in place several measures to safeguard the health of our employees and other stakeholders whilst maintaining business continuity.  This includes providing the necessary PPE and sanitation supplies to all staff and reconfiguring our office environment so that frequent hand sanitation and social distancing can be maintained. Until further notice, all Consilient Health employees will work from home where possible and are available via email, telephone and virtual meetings. All company staff are encouraged to adhere to the latest government guidance.

If you wish to report a suspected adverse reaction or request product information please email To find out more about COVID-19 and get the latest information on the pandemic, please visit the WHO website:

Keep Safe

Distribution agreement signed for Theramex Portfolio in Republic of Ireland and the Nordics

Consilient Health are pleased to announce an agreement with Theramex to market, sell and distribute a range of Theramex’s women’s health and bone health products including Evorel®, Estrena®, Zoely®, Actonel® and Optinate® in the four major Nordic markets and the Republic of Ireland. The agreement also includes an option to distribute Theramex’s pipeline products.

Consilient Health’s CEO, Ahmed Al-Derzi, commented on the deal stating: “Theramex have built, and continue to build, a strong portfolio of medicines in women’s health and bone health. This partnership will build on Consilient Health’s strong track record in these therapy areas and ensure both Theramex and Consilient Health success in the Nordics and Ireland with marketed and pipeline products.” Country Manager for Ireland, Deirdre Kelly added: “Women’s health is a key priority for Consilient Health. With the Theramex product portfolio, we look forward to partnering with Health Care Professionals and other stakeholders to provide a range of clinically relevant medicines and support services that will positively impact the health and lives of Irish female patients.” Henrik Sahl, Country Manager for the Nordics also noted the strong links: “We have had good success in the bone health area and look forward to working with Theramex on their current and future products that support women’s health and wellbeing.”

“We are pleased to have secured this agreement with Consilient Health as it allows Theramex to focus its commercialisation efforts on its core growth markets while leveraging the expertise and experience of Consilient Health in the Nordics and Ireland. We are confident that our combined commitment to women’s health will create further value to the Theramex brand and ensures more women will have access to these important medicines,” commented Robert Stewart, CEO of Theramex.

About Theramex

Theramex is a leading, global speciality pharmaceutical company dedicated to women and their health. With a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis, we support women at every stage of their lives. Our commitment is to listen and understand our patients, serve their needs and offer healthcare solutions to help improve their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them, by providing innovative and effective solutions that care for and support women as they advance through each stage of their lives.

Consilient Health Contact Information

For contact information on your local Consilient Health Ireland representative, please see

Useful Guidance Documents for Health Care Professionals

Regularly updated useful guidance documents for healthcare professionals on COVID-19 are available on the websites of the following:

New Measure Me BMI app developed by Children’s Health Ireland at Temple Street

The Measure Me app has been developed to calculate the BMI SDS and to identify if the child is a healthy weight or overweight. Parents and healthcare professionals need to know whether their child/paediatric patient is overweight so that they can address the issue as soon as possible. Unfortunately, the measurement of weight alone is not at all helpful for parents / healthcare professionals in terms of working our whether their child is at the correct weight. This is because height is also required but while in adults the BMI can be calculated relatively easily, in children the BMI SDS (Standard Deviation Score) must be calculated as children are still growing and adults are not.

The Measure Me app has been developed by Childrens Health Ireland at Temple Street and University College Dublin. It has been unconditionally supported by Consilient Health.

The app is available to download on your mobile or tablet by entering “Measure Me” in the Apple iStore or the Google Play Store, or download immediately by clicking on one of the buttons below.

Cilique now GMS reimbursable for patients as an alternative to Cilest


Health care professionals may be aware that Cilest (250 micrograms norgestimate / 35 micrograms ethinyl estradiol) is being discontinued in Ireland, from July 2019.

Consilient Health provides an alternative medication called Cilique. Cilique contains the same active ingredients – 250 micrograms norgestimate / 35 micrograms ethinyl estradiol – as Cilest.

Cilique is now GMS reimbursable, effective 1st September 2019. Cilique is available to Irish patients in a 3 month pack (21 tablets x 3) at a net wholesale (MIMS) price at €4.65 and reimbursement price of €5.02. Further information on Cilique can be found at and   .

Consilient Health also supply GMS listed oral contraceptives Violite, Azalia and Ovreena and non-GMS listed oral contraceptives Elvina and Elvinette.

For further queries about Cilique or about any Consilient Health medicines or services, please contact Consilient Health on 01 2057760 or

Read more